Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 162,520
  • Shares Outstanding, K 183,618
  • Annual Sales, $ 90,120 K
  • Annual Income, $ -276,060 K
  • 60-Month Beta 0.86
  • Price/Sales 1.83
  • Price/Cash Flow N/A
  • Price/Book 1.29
Trade NKTR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.93
  • Most Recent Earnings $-0.22 on 03/04/24
  • Latest Earnings Date 05/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 127.90% ( +41.87%)
  • Historical Volatility 82.07%
  • IV Percentile 23%
  • IV Rank 11.69%
  • IV High 1,048.38% on 06/20/23
  • IV Low 6.04% on 01/16/24
  • Put/Call Vol Ratio 3.50
  • Today's Volume 9
  • Volume Avg (30-Day) 439
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 7,820
  • Open Int (30-Day) 11,216

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.18
  • Low Estimate -0.22
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7015 +26.67%
on 02/29/24
1.0800 -17.72%
on 03/04/24
+0.1686 (+23.42%)
since 02/28/24
3-Month
0.4800 +85.13%
on 01/18/24
1.0800 -17.72%
on 03/04/24
+0.3366 (+60.98%)
since 12/28/23
52-Week
0.4126 +115.37%
on 11/13/23
1.1200 -20.66%
on 08/07/23
+0.1782 (+25.08%)
since 03/28/23

Most Recent Stories

More News
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced new data for rezpegaldesleukin (REZPEG), a first-in-class selective regulatory T-cell (Treg)...

NKTR : 0.9036 (+2.09%)
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy

/PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will have two presentations for rezpegaldesleukin (REZPEG), a first-in-class...

NKTR : 0.9036 (+2.09%)
Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has entered into a new clinical study collaboration with Cellular Biomedicine Group...

NKTR : 0.9036 (+2.09%)
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at...

NKTR : 0.9036 (+2.09%)
Nektar Therapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in...

NKTR : 0.9036 (+2.09%)
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy data previously generated by Eli Lilly & Company for rezpegaldesleukin...

NKTR : 0.9036 (+2.09%)
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets

/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close...

NKTR : 0.9036 (+2.09%)
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

/PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th...

NKTR : 0.9036 (+2.09%)
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat

Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.

LLY : 786.31 (+1.04%)
NKTR : 0.9036 (+2.09%)
ITRM : 1.6250 (+2.20%)
LRMR : 7.97 (+9.78%)
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of 3.85% and 4.83%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NKTR : 0.9036 (+2.09%)
CTIC : 9.09 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 1.0154
2nd Resistance Point 0.9713
1st Resistance Point 0.9282
Last Price 0.9036
1st Support Level 0.8410
2nd Support Level 0.7969
3rd Support Level 0.7538

See More

52-Week High 1.1200
Last Price 0.9036
Fibonacci 61.8% 0.8498
Fibonacci 50% 0.7663
Fibonacci 38.2% 0.6828
52-Week Low 0.4126

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar